Introduction {#Sec1}
============

For a number of medical research questions, the results produced by the "gold standard" of clinical research---randomized, double-blind, controlled trials (RCTs) of drugs or medical applications---are limited in the evidence they provide regarding potential applications and effects, risks, and patient adherence in a routine medical setting \[[@CR1], [@CR2]\]. Without diminishing the importance and necessity of RCTs in documenting the efficacy and safety of medicinal products, there is a consensus that additional data are required from studies in patients whose diagnosis, treatment, and monitoring exclusively follow normal medical practice \[[@CR3]\], while the patients involved benefit from the increased therapeutic freedom versus participation in a RCT.

Carefully planned, conducted, and evaluated non-interventional studies may be particularly useful in drawing conclusions regarding the effects, safety, and---in some cases---acceptance of therapeutic procedures, medicinal products, or medical devices, based on immediate observation of a wide range of individual circumstances and not on findings in a specific selection of clinical trial patients chosen to meet strictly defined criteria. In a non-interventional study, the medical procedures carried out have the sole purpose of providing the best possible care for the individual patient. Non-interventional studies include a varied range of patients with and without comorbidities and do not dictate additional interventions or instructions beyond the treatment concept based on the needs of the patients concerned. Regulatory authorities in many countries now require non-interventional studies---in most cases following the approval of a new drug---and study design guidelines are now available \[[@CR4]\].

Systematic analysis of data from RCTs versus non-interventional studies has shown virtually no evidence of superiority of RCTs in terms of assessing the effects of medicinal products \[[@CR5]\]. This conclusion applies regardless of the specific design, study population criteria, and data acquisition periods.

Non-interventional studies are conducted in various designs. One such format is a cohort study, in which participants undergo specific medical care and their outcome is monitored and evaluated at certain times \[[@CR1], [@CR6], [@CR7]\]. A prerequisite is that the expected effects in real-life conditions are largely similar to those investigated in RCTs and that the investigating sites are qualified to use the investigational material. This helps to minimize the dropout rate. Non-interventional studies of this kind generally involve large sample sizes and may therefore help to identify rare adverse events (AEs).

Event rates in non-interventional studies may also indicate effects and/or risks attributable to certain factors that do not feature in RCTs because of the strict exclusion criteria. Non-interventional studies, for instance, enable adherence to a new medication or formulation to be analyzed in real life and correlated with treatment response or other parameters. These data may be important if the success of a prescribed long-term therapy very much depends on adherence with the regimen, e.g., in the treatment of patients with hypertension. Hypertension is one of the most common conditions seen in primary care. Untreated, it is associated with a high risk of myocardial infarction, stroke, renal failure, and premature death \[[@CR8], [@CR9]\]. There is an abundance of evidence showing that blood pressure (BP) should be below 150/90 mmHg in patients aged ≥60 years. The corresponding level for younger patients and people with diabetes or renal failure is 140/90 mmHg \[[@CR10]\].

Clinical trial results show that a very large proportion of patients receiving antihypertensive treatment from primary care physicians do not achieve these recommended BP levels \[[@CR11], [@CR12]\]. Many patients require more than one antihypertensive drug for successful BP control \[[@CR13], [@CR14]\] in a regimen encompassing different pharmacologic mechanisms of action. A combination of a beta-blocker such as bisoprolol with a calcium channel blocker such as amlodipine is an established option for successful drug treatment of patients with high BP \[[@CR15]\]. It is also cited repeatedly in international guidelines \[[@CR10]\]. However, prescribing this free-drug treatment regimen presents an adherence challenge for patients, which may considerably jeopardize the desired treatment response \[[@CR16]\]. Hence, it seemed justified to develop and investigate a fixed-dose combination (FDC) of the two active substances in all potentially administered dosage regimens (bisoprolol plus amlodipine: 5 + 5 mg, 10 + 5 mg, 5 + 10 mg, 10 + 10 mg). These FDCs were tested in various clinical trials \[[@CR17]--[@CR19]\] and produced a significant reduction in previously elevated BP at the respective dose levels employed. The FDCs also achieved better results than regimens based on a free-dose combination of the two agents.

To produce additional evidence for these FDCs, an extensive non-interventional study was conducted involving two chronologically separate periods. The first part of the study was evaluated after 4288 patients had been enrolled and treated for 6 months \[[@CR20]\]. Monitoring of the percentage of tablets taken at 6 months revealed a very high rate of good to excellent adherence (\>95%). At the same time, a clinically relevant decline in previously elevated BP was noted (systolic 15%, diastolic 11%), although most patients had been receiving the same doses of bisoprolol and amlodipine in a free combination.

To further verify the accuracy of these results, the study was continued at the same sites, and a number of new sites were added to include results for around 10,000 patients. This enabled data from the first study period to be checked against the data for the whole of this non-interventional study.

Methods {#Sec2}
=======

The plan for this non-interventional study proposed individualized antihypertensive treatment in terms of procedures, dosages, follow-up, and final assessment with four different regimens of the active substances bisoprolol and amlodipine in a FDC: 5 mg bisoprolol plus 5 mg amlodipine, 5 mg bisoprolol plus 10 mg amlodipine, 10 mg bisoprolol plus 5 mg amlodipine, and 10 mg bisoprolol plus 10 mg amlodipine. No additional measures departing from routine care in this patient population were proposed. Investigating sites were at liberty to choose any necessary medical interventions or additional drugs as they saw fit.

Patients aged ≥18 years with essential hypertension were recruited if they had already been switched from a free combination of bisoprolol 5--10 mg/day and amlodipine 5--10 mg/day to the FDC at least 4 weeks prior to recruitment. Reliable contraception was mandatory in women of childbearing age. Exclusion criteria included pregnancy, lactation, any contraindication to the FDC according to the local label, and any other antihypertensive medication.

The primary endpoint was patient adherence under the FDC measured by tablet count (tablets taken/tablets prescribed × 100) and defined as follows: excellent \>90%, good 76--90%, moderate 51--75%, and bad ≤50%. BP was measured in a supine position after at least 5 min rest. All other patient data, clinical findings, and laboratory values were recorded upon availability at study start, after 3 months (voluntary), and after 6 months into case record forms (CRFs). Upon completion of the study, all the entries from the CRFs were transferred to an assessment table (BIAS: Biometric Analysis of Samples, Hanns Ackermann, Frankfurt, Germany).

Access to patient data was restricted exclusively to the investigators. All patients were assigned an ID number before the study to enable anonymous documentation for evaluation purposes. Patients were informed about these data protection measures at the start of the study and asked to sign a consent form to participate in accordance with the conditions described. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the study.

For data analysis, calculation of means with standard deviations, medians with quartiles and Spearman's correlation analyses, Mantel--Haenszel test for contingency tables, and Cohen's D for effect size were used.

Results {#Sec3}
=======

This multicenter non-interventional study included 10,532 patients who were treated in 68 Polish centers. The demographic data of the patients are summarized in Table [1](#Tab1){ref-type="table"}. The mean age was 59 years, with a broad range from 19 to 99 years. There was almost no correlation between BP values and patient age. As shown by the median body mass index (BMI), most of the patients were overweight. Dependence of BP values on BMI could not be determined. A large proportion of patients had concomitant cardiovascular diseases (*N* = 4011, 38.1%) or type 2 diabetes (*N* = 2313, 22%). Angina pectoris (12.3%) and arrhythmia (11.1%) were the most frequent concomitant cardiovascular diseases.Table 1Demographic dataParameter*N* (%)Participants10,532Female5050 (47.9)Male5435 (52.1)Diabetes type 22313 (22)Cardiovascular comorbidities4011 (38.1)Liver disease157 (1.5)Kidney damage347 (3.3)Smoking status Non-smoker4962 (47.1) Smoker2.690 (25.5) Ex-smoker2799 (26.6) No data81 (0.8)Alcohol consumption None3779 (35.9) Not regularly (0--1× weekly)5374 (51.1) Regularly (2--7× weekly)1295 (12.2) No data84 (0.8)ParameterMean (±SD)MedianQ1--Q3Age (years)59 (11)5952--67Height (cm)170.1 (17)170164--177Weight (kg)81.3 (15)8072--90BMI (kg/m^2^)28.1 (4)2825.5--30Systolic BP (mmHg)147.3 (15)148139--160Diastolic BP (mmHg)88.6 (10)9080--95Pulse (beats/minute)76 (10)7668--82Fasting glucose (mg/dL) (*N* = 2429)99.1 (21)9688--105Duration of hypertension (years9.2 (5)72.5--12Duration of free combination treatment prior to switch (months)19.5 (22)147--24Dosages (free combination) (mg/day) Bisoprolol5.5 (2)55--5 Amlodipine6.1 (2)55--5*BMI* body mass index, *BP* blood pressure, *SD* standard deviation

Prior to the switch to the FDC, all patients had been pretreated with a free combination of bisoprolol (mean 5.5 mg once daily) and amlodipine (mean 6.1 mg once daily). The lowest possible dose (5 mg bisoprolol and 5 mg amlodipine once daily) was prescribed for the majority of patients (75%); data in Table [1](#Tab1){ref-type="table"} show that most patients did not reach the target value for systolic BP below 140 mmHg. The average dose in the FDC after switching from the free dose was 5.8 ± 2 mg bisoprolol and 6.4 ± 3 mg amlodipine once daily. In this respect, the switch to the FDC was only associated with minimal dose modification. Thus, when switching from the free to the FDC, no changes in bisoprolol or amlodipine doses were performed in 84% of patients. A correlation between the amount of the respective doses of bisoprolol and amlodipine on BP values before study entry could not be detected.

At the end of the study (Visit 3 after 6 months), data on patient adherence were available for 8830 (82.2%) patients (Table [2](#Tab2){ref-type="table"}). Overall, 3710 patients attended Visit 2 after 3 months, as well as Visit 3 after 6 months. Adherence was stable between the second and the third visits; 80.3% of patients showed an equal share of tablet consumption in both controls. A comparison of the adherence ratings did not show any difference between male and female patients.Table 2Patient adherence at Visit 3 (after 6 months)Adherence (% of prescribed tablets taken)***N*** (%)Excellent (\>90%)7562 (85.6)Good (76--90%)1098 (12.4)Good to excellent (≥76%)8660 (98.1)Moderate (51--75%)145 (1.7)Bad (\<50%)25 (0.3)Total8830 (100.0)

The analysis of data for BP control showed a clinically relevant regression of systolic and diastolic values, although no considerable dose changes were made during the study period (Table [3](#Tab3){ref-type="table"}). BP was measured in a supine position after at least 5 min of rest. Figure [1](#Fig1){ref-type="fig"} shows the proportion of patients with systolic BP changes after 6 months of FDC treatment. It is noteworthy that BP reductions were confirmed for all drug doses tested (Table [4](#Tab4){ref-type="table"}).Table 3BP at study start and after 6 monthsSystolic BP (mmHg)\
*N* = 9435Diastolic BP (mmHg)\
*N* = 9585Mean (±SD)Mean (±SD)Visit 1 (Study start)147.3 (15)87.9 (10)Visit 3 (after 6 months)130.9 (10)79.1 (7)Difference before--after16.6 (16)9.5 (11)Systolic BP (mmHg)\
*N* = 9435Diastolic BP (mmHg)\
*N* = 9585*N* (%)*N* (%)Improvement7754 (82.2)7010 (73.2)No change884 (9.4)1478 (15.4)Worsening797 (8.4)1097 (11.4)*BP* blood pressure, *SD* standard deviationFig. 1Changes in systolic blood pressure as 6 months fixed-dose combination treatment. Proportion of patients (%) showing gradual changesTable 4Changes in systolic and diastolic BP after 6 months based on drug doseReduction of systolic BP mmHgReduction of diastolic BP mmHgMedian1--3 quartilesMedian1--3 quartilesBisoprolol 5 mg--amlodipine 5 mg155--25100--15Bisoprolol 10 mg--amlodipine 5 mg156--25100--20Bisoprolol 5 mg--amlodipine 10 mg157--28100--20Bisoprolol 10 mg--amlodipine 10 mg206--30100--20*BP* blood pressure

Accordingly, remarkable differences can be registered regarding the proportions of patients per quartile between the values at study start and after 6 month if the subdivision of quartiles at study start is maintained (Fig. [2](#Fig2){ref-type="fig"}). The reductions in diastolic BP were very similar to the reductions in systolic BP shown in Fig. [2](#Fig2){ref-type="fig"}. There was a noticeable correlation between BP values prior to the study and the extent of their decline (*r* 0.8).Fig. 2Comparison of proportion of patients quartiles for systolic blood pressure values. *FDC* fixed-dose combination

The importance of adherence for good BP control becomes particularly evident when comparing BP values as a function of patient's behavior. Although only 2% of patients showed moderate or poor adherence, their BP measurements were remarkably higher than those of patients with good to excellent adherence (Table [5](#Tab5){ref-type="table"}). The benefits of adherence on BP control are confirmed by the improvement in pulse pressure by an average of 58.7 mmHG ± 13 (median 60) at study start versus 51.7 mmHg ± 11 (median 50) after 6 months of treatment. All patients were asked whether they would choose the free combination or the FDC; approximately 97% of patients preferred the FDC.Table 5Correlation of BP after 6 months and adherenceAdherenceSystolic BP (mmHg)Diastolic BP (mmHg)*N* = 8830Mean (± SD)Mean (SD)MedianMedianQ1--Q3Q1--Q3Excellent (\>90%)\
*N* = 7562130.5 (9)79.1 (7)13080125--13675--83Good (76--90%)\
*N* = 1098132.2 (11)79.4 (8)13080125--14075--85Moderate (51--75%)\
*N* = 145137.1 (17)76.7 (10)14080120--15070--85Bad (\<50%)\
*N* = 25144.1 (17)79.8 (9)14080127--16070--88*BP* blood pressure

Although all patients had been treated with a free-dose combination of bisoprolol and amlodipine and switched to the FDC at least 4 weeks before starting the study, BP measurement at study start showed differences in systolic readings, which were attributable to the respective comorbidities (Table [6](#Tab6){ref-type="table"}). In contrast, patients who reported none of the listed comorbidities had a lower systolic BP (average 145 ± 10 mmHg).Table 6Dependence on systolic BP values and comorbidities prior to study entryComorbidityDisease presentDisease absentSystolic BP (mmHg)Systolic BP (mmHg)Mean (±SD)Q1--median--Q3Mean (±SD)Q1--median--Q3Diabetes150.7 (16)140--150--160146.4 (±15)135--145--158Cardiovascular diseases149.5 (16)140--150--160145.9 (±15)135--145--160Renal diseases149.1 (17)140--150--160147.2 (15)139--147--160*BP* blood pressure

After 6 months of treatment with the FDC of bisoprolol and amlodipine with no major dose changes, differences in systolic BP in relation to comorbidities were no longer evident (with diabetes 130.5 ± 10 mmHg, without diabetes 131.9 ± 10 mmHg; with cardiovascular diseases 130.4 ± 10 mmHg, without cardiovascular diseases 131.5 ± 10 mmHg; with renal diseases 130.9 ± 10 mmHg, without renal diseases 131.2 ± 11 mmHg).

Another improvement observed during the study was a considerable reduction in heart rate from an average of 75 ± 10 to 68.6 ± 10 bpm, which can also help to reduce the health risk for these patients.

Safety Evaluation {#Sec4}
-----------------

In total, 89 AEs were reported in 70 patients (0.7%). The majority of these were edema (41, 46.1%), headache (7, 7.8%), dizziness (6, 6.7%), and bradycardia, nausea, and skin burning/redness (4, 4.5% each). Only three AEs (3.4%) were considered serious, one case of atrial fibrillation (not related), one case of chronic heart failure worsening, and one head injury leading to death (not related). Just nine patients (0.09%) discontinued the study due to AEs, including lower limb or ankle swelling or other edema, nausea/malaise, skin burning/redness/flushing, congestive heart failure worsening/decompensation, dyspnea, or arrhythmia.

There were only a few laboratory values documented: fasting plasma glucose, HbA1C, serum creatinine, aspartate aminotransferase, and alanine aminotransferase. There were no noticeable changes in these parameters during the study.

Discussion {#Sec5}
==========

Many patients with hypertension have other concomitant conditions, including lipid abnormalities, renal disease, diabetes, cardiovascular events, obesity, and/or smoking. The success of treating hypertension has been limited, and despite well-established approaches to diagnosis and treatment, fewer than half of all hypertensive patients have adequately controlled BP \[[@CR21]\].

The most important goal of treatment is to manage hypertension and to deal with the other identified risk factors for cardiovascular disease. For hypertension, the treatment goal for systolic BP is usually \<140 mmHg and for diastolic BP \<90 mmHg. Most patients will require more than one drug to efficiently control their BP. The choice of drugs will be influenced by many different aspects and conditions (e.g., diabetes and coronary disease). Generally, there are many clinically proven recommendations for drug selection either for patients whose primary problem is hypertension, or for patients who have a major comorbidity associated with their hypertension.

As regards calcium channel blockers, most experience with these agents has been gained with the dihydropyridines, such as amlodipine and nifedipine, which have shown beneficial effects on cardiovascular and stroke outcomes in hypertension trials \[[@CR22]\]. Beta-blockers reduce cardiac output and decrease the release of renin from the kidney. They have strong clinical outcome benefits in patients with histories of myocardial infarction and heart failure and are effective in the management of angina pectoris \[[@CR23], [@CR24]\].

However, patients find having to take a large number of tablets burdensome \[[@CR24]\]. This manifests itself in non-compliance with treatment as directed, or discontinuation of treatment \[[@CR25]\]. Failure of hypertensive treatment is demonstrably attributable mainly to poor adherence to treatment on the part of patients \[[@CR26]\]. European guidelines for the management of hypertension accordingly recommend treatment with a combination tablet \[[@CR10]\] and the results of various studies indicate the clinical relevance of this recommendation \[[@CR25], [@CR27], [@CR28]\].

The study results available to date demonstrate the relationship between successful BP management and patient adherence, in particular since the results from the first study period in more than 4000 patients corresponded fully to those generated in the total population of more than 10,000 patients \[[@CR20]\].

The cohort recruited in this study can be considered as representative of real-life hypertension treatment. The study covered a wide range of ages: 23% of patients were aged \<50 years and 15% were aged \>70 years, thus, most patients were aged between 50 and 70 years. Good to excellent adherence was observed in more than 95% of patients, and approximately 86% of prescribed tablets were taken. It can be assumed that the investigators helped to convince patients through intensive discourse and that the consent of patients to take part in this study likewise contributed to this outcome. The consequence is a clinically important decline in previously elevated systolic BP in 82% of patients, and diastolic BP in 73% of patients; BP declined overall by 11 percentage points. A therapeutic goal has hence been met that is in line with international guidelines. Regardless of the doses prescribed in each case, similar reductions in BP were achieved. Patients with very high BP benefitted most from the use of the FDC.

Comparison of results of the preceding study with those of the overall group identified no differences in the changes in BP, which is an indication of rigorous and meticulous project conduct. The results do not contradict those obtained in investigational controlled trials \[[@CR18], [@CR19]\]. To that extent, the results of this non-interventional study tend to contradict the commonly postulated study design hierarchy and confirm the insights of other authors on this subject \[[@CR29], [@CR30]\].

Beyond that, this non-interventional study provides insights into additional factors in the lives of hypertension patients, in particular with regard to their comorbidities and treatment outcomes in these circumstances while receiving routine medical care. The absence of strict inclusion criteria, such as apply in RCTS, enables data to be collected from patients with a variety of comorbidities that may have a meaningful impact on their condition and may constitute additional risks.

The results of this study demonstrate that systematic adherence with treatment instructions contributes to a clinically relevant improvement in BP control in these patients too. The high acceptance of the FDC by the patient was also shown by the fact that 97% of patients preferred the FDC over the free combination at study end.

Not only BP, but also the pulse pressure and the heart rate as independent risk factors for cardiovascular disease were improved in the study. As far as the safety of treatment is concerned, no AEs or reactions outside the known profile for these active pharmaceutical ingredients occurred during the 6-month period.

The analysis of the study after 6 months was based on the data of 8830 patients, which represented a dropout rate of 17%. Experiences in implementing observational studies show that such a loss of data is quite common and inevitable, and is unlikely to influence the overall result of the study.

When evaluating the data from this study, we paid more attention to clinically relevant results than statistically calculated differences or correlations, because the high number of cases could lead to incorrect conclusions by assessing statistical results only. To that extent, the assessment of the results was more orientated to differences in the confidence intervals and the *C* values of the effect size taken.

Conclusion {#Sec6}
==========

These study results suggest that high adherence rates under a FDC of bisoprolol and amlodipine may lead to better BP control and, thus, to risk reduction for cardiovascular events. The implementation of an observational study with such a high number of patients provides a wide range of information for daily practice and enables us to draw conclusions about the relationships between the drug's effect and additional factors.
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